Overnight switch from carbamazepine to eslicarbazepine in a real-life clinical scenario: a retrospective study
Neurological Sciences · 2024
DOI: 10.1007/s10072-024-07354-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurological Sciences, 2024. Verfasst von Biagio Maria Sancetta und 9 weiteren Autor:innen. Beteiligte Einrichtung: UOC Neurologia, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200, 00128, Rome, Italy. biagio.sancetta@unicampus.i…. Hauptthemen laut MEDLINE: Carbamazepine, Anticonvulsants, Dibenzazepines, Epilepsy. Die Arbeit nennt 53 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Carbamazepine (CBZ) is a first-choice anti-seizure medication (ASM) whose efficacy is often invalidated by adverse effects (AEs). Eslicarbazepine (ESL) is a structural derivative of CBZ with better pharmacokinetic/tolerability profiles. We describe our experience of the overnight CBZ to ESL switch in people with epilepsy (PwE) to improve seizure control, AEs, and ASMs adherence. METHODS: We retrospectively included 19 PwE (12 females, 53 ± 21 years old) who underwent CBZ to ESL overnight switch due to single/multiple issues: poor efficacy (pEff, N = 8, 42%), tolerability (pToll, N = 11, 58%), adherence (pAdh, N = 2, 10%). 9/19 (47%) had psychiatric comorbidities. Clinical variables, seizure frequency, and AEs were recorded at switch time (T0) after 3.5 ± 3 (T1) and 6.5 ± 1.5 months (T2). RESULTS: At T1, in pEff group, 1/8 (13%) was seizure free, 2/8 (25%) were responders (> 50% seizure reduction), 2/8 (25%) had no seizure changes, 3/8 (37%) had seizure worsening; the latter were those with the most severe epilepsy and encephalopathy. In pToll group, all PwE experienced AEs disappearance/amelioration. In pAdh group, all PwE reported adherence amelioration. Four dropouts. At T2, no changes were recorded within groups, while in the whole sample, 6/15 (40%) were responders, and 4/15 (27%) were seizure-free. No one complained of Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation psychiatric worsening, while 6/19 (32%) experienced mood/behavior benefits. CONCLUSIONS: CBZ to ESL overnight switch offers an opportunity to improve efficacy, tolerability, adherence, and psychiatric symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UOC Neurologia, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200, 00128, Rome, Italy. biagio.sancetta@unicampus.it.
- Research Unit of Neurology, Neurophysiology and Neurobiology, Department of Medicine and Surgery, Università Campus Bio-Medico Di Roma, Via Alvaro del Portillo, 21, 00128, Rome, Italy. biagio.sancetta@unicampus.it.
- UOC Neurologia, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200, 00128, Rome, Italy.
- Research Unit of Neurology, Neurophysiology and Neurobiology, Department of Medicine and Surgery, Università Campus Bio-Medico Di Roma, Via Alvaro del Portillo, 21, 00128, Rome, Italy.
- Istituti Clinici Scientifici Maugeri IRCCS, Neurorehabilitation Department of the Milano Institute, Milan, Italy.
Zitieren
APA
Sancetta, B. M., Ricci, L., Lanzone, J., Boscarino, M., Narducci, F., Lippa, G., Nesta, M., Di Lazzaro, V., Tombini, M., & Assenza, G. (2024). Overnight switch from carbamazepine to eslicarbazepine in a real-life clinical scenario: a retrospective study. Neurological Sciences. https://doi.org/10.1007/s10072-024-07354-6
Vancouver
Sancetta BM, Ricci L, Lanzone J, Boscarino M, Narducci F, Lippa G, et al. Overnight switch from carbamazepine to eslicarbazepine in a real-life clinical scenario: a retrospective study. Neurological Sciences. 2024. doi:10.1007/s10072-024-07354-6
BibTeX
@article{Sancetta2024,
author = {Sancetta, Biagio Maria and Ricci, Lorenzo and Lanzone, Jacopo and Boscarino, Marilisa and Narducci, Flavia and Lippa, Giulia and Nesta, Marianna and Di Lazzaro, Vincenzo and Tombini, Mario and Assenza, Giovanni},
title = {Overnight switch from carbamazepine to eslicarbazepine in a real-life clinical scenario: a retrospective study},
journal = {Neurological Sciences},
year = {2024},
doi = {10.1007/s10072-024-07354-6}
}
EUVIMED